PHGDH is required for germinal center formation and is a therapeutic target in <i>MYC</i> -driven lymphoma

Annalisa D’Avola(The Francis Crick Institute), John C. Riches(Queen Mary University of London)

bioRxiv (Cold Spring Harbor Laboratory)

November 12, 2021

10.1101/2021.11.11.468272

Cited by 0

Related Papers

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

|Blood|2020|657

Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies

|Clinical Lymphoma Myeloma & Leukemia|2024|5

CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies

|Clinical Lymphoma Myeloma & Leukemia|2024|2